After announcing a phase 3 launch based on positive midstage results, iTeos and GSK are finally sharing the highlights from the phase 2 TIGIT trial, revealing a more than 30% difference in confirmed overall response rates between the investigational treatment versus monotherapy.

A targeted immunotherapy being developed by iTeos Therapeutics and GSK, it was reported at #ESMO, delivered promising response rates in patients with a type of lung cancer.

The results of the GALAXIES Lung-02 study reported at the ESMO congress in Barcelona showed that the drug – added to GSK's PD-1 inhibitor Jemperli (dostarlimab) – achieved a higher objective response rate than Jemperli on its own.

The published belrestotug/dostarlimab data is still too immature to prove the combination’s capability to disrupt the NSCLC treatment paradigm.

Teos Therapeutics (NASDAQ:ITOS) announced Saturday that its experimental cancer doublet therapy developed with GSK (NYSE:GSK) outperformed the British drugmaker’s FDA-approved anti-PD-1 therapy dostarlimab,